Answer:
Obesity is excess weight, defined as a body mass index (BMI) ≥30 kg/m2. Complications include cardiovascular disorders (especially in people with excess belly fat), diabetes, certain cancers, gallstone disease, fatty liver, cirrhosis, degenerative joint disease, and reproductive disorders. in men and women, psychological distress, and premature death for those with BMI ≥ 35. Diagnosis is based on body mass index. Treatment includes lifestyle changes (eg, in diet, physical activity, and behavior), and, for some patients, medications or weight loss surgery (weight loss).
So it's a disease, not a behavioral problem
the state of being protected against the unauthorized use of information, especially electronic data, or the measures taken to achieve this.
Answer:
Eating high quality foods that cobatojs lots of vitamins minerals and antioxidants nourishes the brain and protects it from oxidative stress the "waste" produced when the body uses oxygen , which can damage cells.
The right answer is Stimulants speed up the central nervous system
A stimulant is a substance that increases the activity of the sympathetic nervous system facilitating or improving certain functions of the body. Common stimulants include caffeine in tea and coffee, and nicotine in large amounts in tobacco.
Stimulating substances increase the activity of the sympathetic system quite gradually but in a prolonged manner, being distinguished from those having a rather fast but relatively limited exciting effect.
Answer:
Hi
False
Explanation:
Since the way to protect the innovation of a product, in this case of a medicine, is by giving it a period of time in which it has exclusivity of sale in the market. The duration of the patent is 20 years from the date of filing of the patent application. Once this time passes, any manufacturer that meets the quality requirements can produce that same medicine.
In some countries, it is possible to obtain a longer period of protection for pharmaceutical products. This is awarded as compensation for the loss of the actual period of protection for possible delays in obtaining approval of the drug for certification.
